Peptide Analog

A peptide analog is a designed variant of a parent peptide: residues are substituted, deleted or added, or the molecule is chemically modified, while enough of the binding surface survives that it still engages the original receptor. The changes target a known liability — a protease cleavage site, rapid renal filtration, poor solubility, activity at an unwanted receptor subtype. Modification may be to the sequence, to the termini, or to a side chain through acylation, PEGylation or cyclisation.

The GLP-1 series shows the method. Liraglutide is human GLP-1 with one residue substitution and a C16 fatty acid attached through a glutamate spacer, which binds albumin and stretches the half-life from minutes to hours. Semaglutide adds an unnatural residue at position 8 that blocks DPP-4 cleavage plus a C18 diacid, reaching roughly a week. Desmopressin is vasopressin deaminated at the N-terminus with a D-arginine substitution, which strips the pressor activity.

Analog is a statement about ancestry, not equivalence. Each of those molecules ran its own trials and holds its own approval, because a single-residue change can alter potency, selectivity, immunogenicity and clearance route at once. Knowing a compound is an analog of something familiar tells you where to look for its pharmacology; it does not carry over the parent's efficacy, safety profile or regulatory standing.

The misuse is predictable. Grey-market listings describe unapproved compounds as analogs of approved drugs, inviting the reader to import the approved drug's evidence base wholesale. The word also implies a modification is trivial when it is the entire drug: the difference between native GLP-1, cleared in about two minutes, and a weekly analog is one substitution and one fatty acid.